IE56147B1 - 3-pyridyl-5-alkoxy-(or-phenoxy or benzyloxy)-pyrazole derivatives,a process for the preparation thereof and medical use thereof - Google Patents
3-pyridyl-5-alkoxy-(or-phenoxy or benzyloxy)-pyrazole derivatives,a process for the preparation thereof and medical use thereofInfo
- Publication number
- IE56147B1 IE56147B1 IE1610/83A IE161083A IE56147B1 IE 56147 B1 IE56147 B1 IE 56147B1 IE 1610/83 A IE1610/83 A IE 1610/83A IE 161083 A IE161083 A IE 161083A IE 56147 B1 IE56147 B1 IE 56147B1
- Authority
- IE
- Ireland
- Prior art keywords
- pyridyl
- group
- pyrazole
- pharmaceutically acceptable
- alkoxy
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 14
- 238000002360 preparation method Methods 0.000 title claims description 5
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 title description 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 238000005804 alkylation reaction Methods 0.000 claims abstract description 11
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims abstract description 10
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims abstract description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 9
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims abstract description 8
- 230000029936 alkylation Effects 0.000 claims abstract description 7
- 239000002253 acid Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 14
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000004076 pyridyl group Chemical group 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Chemical compound CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- ZGSNZVRXASCXRP-UHFFFAOYSA-N 5-methoxy-1h-pyrazole Chemical compound COC=1C=CNN=1 ZGSNZVRXASCXRP-UHFFFAOYSA-N 0.000 claims description 4
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical group C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- LLTUZNZRMLDFKN-UHFFFAOYSA-N 4-(3-methoxy-4-methyl-1h-pyrazol-5-yl)pyridine Chemical compound CC1=C(OC)NN=C1C1=CC=NC=C1 LLTUZNZRMLDFKN-UHFFFAOYSA-N 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 abstract description 3
- 230000007812 deficiency Effects 0.000 abstract description 2
- PUJFAVBKNLIGFV-UHFFFAOYSA-N 2-pyridin-3-yl-4h-pyrazol-3-one Chemical compound O=C1CC=NN1C1=CC=CN=C1 PUJFAVBKNLIGFV-UHFFFAOYSA-N 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 239000000203 mixture Substances 0.000 description 10
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 6
- -1 2-methyl-4-pyridyl Chemical group 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002329 infrared spectrum Methods 0.000 description 5
- ZRHUHDUEXWHZMA-UHFFFAOYSA-N 1,4-dihydropyrazol-5-one Chemical compound O=C1CC=NN1 ZRHUHDUEXWHZMA-UHFFFAOYSA-N 0.000 description 3
- LLJRXVHJOJRCSM-UHFFFAOYSA-N 3-pyridin-4-yl-1H-indole Chemical group C=1NC2=CC=CC=C2C=1C1=CC=NC=C1 LLJRXVHJOJRCSM-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 230000003177 cardiotonic effect Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000000297 inotrophic effect Effects 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 150000003217 pyrazoles Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical group OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 1
- OZDPHXFTSZWONB-UHFFFAOYSA-N 2-(3-methoxy-4-methyl-1h-pyrazol-5-yl)pyridine Chemical compound CC1=C(OC)NN=C1C1=CC=CC=N1 OZDPHXFTSZWONB-UHFFFAOYSA-N 0.000 description 1
- CLQBFONDKIKQJQ-UHFFFAOYSA-N 3-(3-methoxy-4-methyl-1h-pyrazol-5-yl)pyridine Chemical compound CC1=C(OC)NN=C1C1=CC=CN=C1 CLQBFONDKIKQJQ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- VKZVUZGCASBXKO-UHFFFAOYSA-N 4-(3-methoxy-1h-pyrazol-5-yl)pyridine Chemical compound N1C(OC)=CC(C=2C=CN=CC=2)=N1 VKZVUZGCASBXKO-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- KNFFXWXJAAUGMX-UHFFFAOYSA-N 4-(4-benzyl-3-methoxy-1h-pyrazol-5-yl)pyridine Chemical compound COC=1NN=C(C=2C=CN=CC=2)C=1CC1=CC=CC=C1 KNFFXWXJAAUGMX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- ZDXRSMCFRIFFNK-UHFFFAOYSA-N ethyl 3-pyridin-4-ylpropanoate Chemical compound CCOC(=O)CCC1=CC=NC=C1 ZDXRSMCFRIFFNK-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8212176A FR2529891A1 (fr) | 1982-07-12 | 1982-07-12 | Derives du pyridyl-3 alcoxy-5 pyrazole, procede de preparation et application en therapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE831610L IE831610L (en) | 1984-01-12 |
| IE56147B1 true IE56147B1 (en) | 1991-05-08 |
Family
ID=9275904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE1610/83A IE56147B1 (en) | 1982-07-12 | 1983-07-11 | 3-pyridyl-5-alkoxy-(or-phenoxy or benzyloxy)-pyrazole derivatives,a process for the preparation thereof and medical use thereof |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4526895A (enExample) |
| EP (1) | EP0099815B1 (enExample) |
| AT (1) | ATE20063T1 (enExample) |
| DE (1) | DE3363740D1 (enExample) |
| FR (1) | FR2529891A1 (enExample) |
| IE (1) | IE56147B1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666913A (en) * | 1985-11-22 | 1987-05-19 | William H. Rorer, Inc. | Hydroxy and aminothiazolyl-benzodiazinone compounds, cardiotonic compositions including the same, and their uses |
| EP0941222A2 (en) | 1996-11-12 | 1999-09-15 | Novartis AG | Pyrazole derivatives useful as herbicides |
| AR012117A1 (es) * | 1997-03-21 | 2000-09-27 | Novartis Ag | Compuestos herbicidas, proceso para su preparacion, compuestos intermediarios para su exclusivo uso en dicho proceso, composicion herbicidae inhibidora del crecimiento de las plantas, metodo para controlar el crecimiento indeseado de plantas y uso de dicha composicion en el control de |
| EP1080088A1 (en) * | 1998-05-20 | 2001-03-07 | Novartis AG | Pyridyl-pyrazole derivatives, process for their preparation, and their use as herbicides |
| EP1550668A4 (en) * | 2002-10-04 | 2008-10-01 | Kissei Pharmaceutical | PYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION COMPRISING THE DERIVATIVE, MEDICINAL USE THEREOF, AND INTERMEDIATE ENTERING THE PRODUCTION THEREOF |
| WO2004113359A1 (ja) * | 2003-06-20 | 2004-12-29 | Kissei Pharmaceutical Co., Ltd. | ピラゾール誘導体、それを含有する医薬組成物及びその製造中間体 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1385811A (en) * | 1972-01-14 | 1975-03-05 | Nativelle Sa Ets | 1-amino pyrazole derivatives and pharmaceutical compositions containing them |
| US4072746A (en) * | 1975-10-14 | 1978-02-07 | Sterling Drug Inc. | 3-Amino-5-(pyridinyl)-2(1H)-pyridinones |
| IL61501A (en) * | 1979-11-26 | 1984-06-29 | Sterling Drug Inc | 5-(pyridinyl)-2(1h)-pyridinones,their preparation and pharmaceutical compositions containing them |
| DE3106460A1 (de) * | 1980-03-03 | 1982-01-28 | Sandoz-Patent-GmbH, 7850 Lörrach | 2(1h)-pyridinon-derivate, ihre herstellung und sie enthaltende pharmazeutische zubereitungen |
| NZ196844A (en) * | 1980-04-28 | 1984-04-27 | Sterling Drug Inc | 4-substituted-6-pyrid-(3 or 4)-ylpyridazin-3(2h)-ones |
-
1982
- 1982-07-12 FR FR8212176A patent/FR2529891A1/fr active Granted
-
1983
- 1983-07-11 EP EP83401427A patent/EP0099815B1/fr not_active Expired
- 1983-07-11 DE DE8383401427T patent/DE3363740D1/de not_active Expired
- 1983-07-11 AT AT83401427T patent/ATE20063T1/de not_active IP Right Cessation
- 1983-07-11 IE IE1610/83A patent/IE56147B1/en not_active IP Right Cessation
- 1983-07-12 US US06/513,190 patent/US4526895A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE3363740D1 (en) | 1986-07-03 |
| FR2529891A1 (fr) | 1984-01-13 |
| ATE20063T1 (de) | 1986-06-15 |
| IE831610L (en) | 1984-01-12 |
| FR2529891B1 (enExample) | 1985-01-11 |
| EP0099815B1 (fr) | 1986-05-28 |
| US4526895A (en) | 1985-07-02 |
| EP0099815A1 (fr) | 1984-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5425057B2 (ja) | Ｈｓｐ９０阻害剤としてのキナゾリン−オキシム誘導体 | |
| EP0821685B1 (en) | Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists | |
| TW403746B (en) | New substituted pyrazole derivatives | |
| CA2043709C (en) | Antimigraine alkoxypyrimidine derivatives | |
| WO2000044743A1 (en) | Amide derivatives and drug compositions | |
| EP0397060A2 (de) | Maleinimid-Derivate und deren Verwendung als Arzneimittel | |
| MXPA06013593A (es) | Nuevos derivados de piridazin-3(2h)-ona. | |
| JP2001505550A (ja) | 新規へテロシクリルメチル置換ピラゾール誘導体 | |
| JPH11501923A (ja) | ６−置換ピラゾロ〔３，４−ｄ〕ピリミジン−４−オン並びにそれらを含有する組成物および使用方法 | |
| EP0856000A1 (en) | 1,3,5-trisubstituted pyrazoles for treament of inflammation | |
| CZ283993A3 (en) | Phenoxy- and phenoxyalkyl piperidines as antiviral active substances | |
| CN119053601A (zh) | 泛素特异性蛋白酶1(usp1)的小分子抑制剂及其用途 | |
| US5182280A (en) | Derivatives of benzimidazole and their use as antihistamines | |
| JP2005529843A (ja) | トリアゾロ［４，３−ａ］ピリド［２，３−ｄ］ピリミジン−５−オン、それらを含有する組成物、その製造方法及び使用 | |
| JP2000281654A (ja) | イソキノリン誘導体 | |
| EP2041119A1 (fr) | Derives de pyrazolylbenzimidazole, compositions les contenant et leur utilisation | |
| NZ207914A (en) | Indeno-pyridazinones and pharmaceutical compositions | |
| WO2024234821A1 (zh) | 三并环酰胺化合物、包含其的药物组合物及其制备方法和用途 | |
| WO2022057787A1 (zh) | 一类细胞程序性坏死抑制剂及其制备方法和用途 | |
| IE56147B1 (en) | 3-pyridyl-5-alkoxy-(or-phenoxy or benzyloxy)-pyrazole derivatives,a process for the preparation thereof and medical use thereof | |
| CN117402161A (zh) | 一种具有fgfr抑制作用的亚砜亚胺类化合物、包含其的药物组合物及其用途 | |
| MX2011004903A (es) | Pirrolidinas. | |
| PL97275B1 (pl) | Sposob wytwarzania nowych pochodnych tienotriazolodwuazepiny | |
| RU2128175C1 (ru) | Конденсированный пиридазин или его фармакологически приемлемая соль, средство, проявляющее ингибирующую активность в отношении циклической гмф- фосфодиэстеразы | |
| CN119977947A (zh) | Prmt5抑制剂、其药物组合物及其在药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed |